Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

NCT06449209 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06449209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 5, 2024
Completion date
February 29, 2028
Enrollment
110 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer, small-cell lung cancer